Viking Therapeutics (VKTX) Total Liabilities (2014 - 2026)

Viking Therapeutics has disclosed Total Liabilities across 13 years of filings, most recently posting $113.6 million for Q2 2026.

• In Q2 2026, Total Liabilities rose 250.67% year-over-year to $113.6 million; the TTM figure through Jun 2026 stood at $113.6 million (up 250.67% YoY), while the FY2025 annual figure was $76.7 million, up 173.39% from the prior year.
• Total Liabilities came in at $113.6 million for Q2 2026 at Viking Therapeutics, up from $106.3 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $113.6 million in Q2 2026 to a low of $12.8 million in Q1 2022.
• Average Total Liabilities over 5 years is $34.6 million, with a median of $24.5 million recorded in 2022.
• Year-over-year, Total Liabilities tumbled 40.3% in 2025 and surged 429.64% in 2026.
• Over 5 years, Total Liabilities stood at $23.2 million in 2022, then retreated by 13.51% to $20.1 million in 2023, then surged by 39.72% to $28.0 million in 2024, then jumped by 173.39% to $76.7 million in 2025, then jumped by 48.15% to $113.6 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $113.6 million in Q2 2026, $106.3 million in Q1 2026, and $76.7 million in Q4 2025.